Byondis
Frans Pennings is an experienced professional in quality assurance and analytical development within the pharmaceutical industry. Currently serving as a QA Specialist at Byondis since January 2020, Frans is responsible for directing, coordinating, and executing QA systems-related tasks. Prior experiences include roles as Group Lead GMP Compliance and Head of Quality Control at Synthon, and leadership positions in Quality Control and Pharmaceutical Analysis at various organizations such as Charles River Laboratories and MSD. Throughout a career spanning several decades, Frans has developed expertise in leading teams, managing compliance, and coordinating projects across multiple departments, alongside significant technical experience in analytical methodologies. Holding a Bachelor’s degree in Biochemistry, Frans first gained laboratory experience at Cehave Landbouwbelang.
This person is not in any teams
This person is not in any offices
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.